P.A.W. Capital’s Galmed Pharmaceuticals GLMD Stock Holding History

P.A.W. Capital’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-139	Closed	-$318K	–	59
2022 Q1	$318K	Hold	139	–	–	0.33%	59
2021 Q4	$364K	Hold	139	–	–	0.33%	59
2021 Q3	$558K	Hold	139	–	–	0.5%	62
2021 Q2	$608K	Hold	139	–	–	0.51%	61
2021 Q1	$686K	Hold	139	–	–	0.6%	57
2020 Q4	$622K	Hold	139	–	–	0.55%	56
2020 Q3	$706K	Buy	139 +70	+101%	+$457K	0.77%	27
2020 Q2	$478K	Hold	69	–	–	0.54%	51
2020 Q1	$346K	Hold	69	–	–	0.47%	55
2019 Q4	$578K	Buy	69 +20	+41%	+$137K	0.62%	53
2019 Q3	$335K	Hold	49	–	–	0.42%	59
2019 Q2	$515K	Sell	49 -14	-22%	-$144K	0.56%	58
2019 Q1	$735K	Hold	63	–	–	0.73%	31
2018 Q4	$615K	Hold	63	–	–	0.77%	40
2018 Q3	$1.22M	Sell	63 -3	-5%	-$56.2K	1.3%	24
2018 Q2	$1.13M	Sell	66 -3	-4%	-$34.7K	1.14%	27
2018 Q1	$557K	Sell	69 -4	-5%	-$46.6K	0.67%	53
2017 Q4	$961K	Hold	73	–	–	1.21%	29
2017 Q3	$960K	Sell	73 -10	-12%	-$111K	1.01%	43
2017 Q2	$744K	Hold	83	–	–	0.75%	53
2017 Q1	$587K	Hold	83	–	–	0.59%	69
2016 Q4	$421K	Buy	83 +41	+98%	+$217K	0.48%	65
2016 Q3	$266K	Buy	+42	New	+$253K	0.29%	66

Other funds holding GLMD

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

WWM

Western Wealth Management Golden, Colorado $3.06B AUM 26.31% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

P.A.W. Capital's GLMD Position: Q2 2022 in Review

P.A.W. Capital sold out of Galmed Pharmaceuticals (GLMD) in Q2 2022, closing a stake of 139 shares — an estimated $318K sold.

P.A.W. Capital first reported a position in GLMD in Q3 2016 and held it in 23 quarters. The position peaked at $1.22M in Q3 2018. 21 funds tracked by Wall St. Rank hold GLMD as of Q2 2022.

P.A.W. Capital reported no remaining Galmed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
P.A.W. Capital sold 139 Galmed Pharmaceuticals shares in Q2 2022, an estimated $318K.
P.A.W. Capital first reported a position in Galmed Pharmaceuticals in Q3 2016 and held it in 23 quarters.
P.A.W. Capital's Galmed Pharmaceuticals position peaked at $1.22M in Q3 2018.
21 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2022.

Based on P.A.W. Capital's 13F filing for Q2 2022, filed 13 Jul 2022.